Literature DB >> 20350633

Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections.

Hartmut Lode1.   

Abstract

Recent data suggest that adverse events (AEs) associated with the use of antimicrobial drugs are a major safety concern, with antibiotics implicated in a significant proportion (approximately 20%) of all drug-related emergency department visits in the United States. Although most of these visits are attributable to allergic reactions (79%), certain commonly prescribed antibiotics are notable contributors to conditions that range in nature from gastrointestinal to neurologic and/or psychiatric--particularly after ED visits are adjusted per outpatient prescription visits. This article reviews medically significant AEs of agents included in the major antimicrobial classes--AEs that may be underappreciated by general practitioners. Considerable attention is devoted to the fluoroquinolone agents. Also discussed are the assessment procedures of regulatory agencies in Europe and the United States that are in place to evaluate antimicrobial safety more accurately. Offsetting potential risks and benefits associated with currently available antimicrobials in a climate in which new agents are desperately needed to combat continually evolving multiresistant pathogens remains an interesting dilemma in antimicrobial therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350633     DOI: 10.1016/j.amjmed.2010.02.004

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.

Authors:  Carl Llor; Lars Bjerrum
Journal:  Ther Adv Drug Saf       Date:  2014-12

2.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

3.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

4.  Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.

Authors:  Francesco Blasi; Paolo Tarsia; Marco Mantero; Letizia C Morlacchi; Federico Piffer
Journal:  Ther Clin Risk Manag       Date:  2013-02-12       Impact factor: 2.423

5.  Antibiotic preferences for childhood pneumonia vary by physician type and European region.

Authors:  Julia A Bielicki; Charlotte I S Barker; Alike W van der Velden; Mike Sharland; Diego van Esso; Adamos Hadjipanayis; Stefano Del Torso; Zachi Grossman
Journal:  ERJ Open Res       Date:  2016-04-29

6.  Antibiotic prescribing in patients with self-reported sore throat.

Authors:  Nishchay Mehta; Anne Schilder; Ellen Fragaszy; Hannah E R Evans; Oliver Dukes; Logan Manikam; Paul Little; Sarah C Smith; Andrew Hayward
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

7.  An Efflux Pumps Inhibitor Significantly Improved the Antibacterial Activity of Botanicals from Plectranthus glandulosus towards MDR Phenotypes.

Authors:  Gravalain Nanmeni; Alex T Tedonkeu; Aimé G Fankam; Armelle T Mbaveng; Brice E N Wamba; Paul Nayim; Gabin T M Bitchagno; Raïssa T Nzogong; Maurice D Awouafack; Mathieu Tene; Veronique P Beng; Victor Kuete
Journal:  ScientificWorldJournal       Date:  2021-05-11

8.  Drug use and upper gastrointestinal complications in children: a case-control study.

Authors:  Manuela Bianciotto; Elena Chiappini; Irene Raffaldi; Clara Gabiano; Pier-Angelo Tovo; Sara Sollai; Maurizio de Martino; Francesco Mannelli; Vincenzo Tipo; Roberto Da Cas; Giuseppe Traversa; Francesca Menniti-Ippolito
Journal:  Arch Dis Child       Date:  2012-12-21       Impact factor: 3.791

9.  Evaluating the therapeutic efficacy, tolerability, and safety of an aqueous extract of Costus speciosus rhizome in acute pharyngitis and acute tonsillitis. A pilot study.

Authors:  Zainab A Bakhsh; Talal A Al-Khatib; Saad M Al-Muhayawi; Sufian M ElAssouli; Iman A Elfiky; Samiha A Mourad
Journal:  Saudi Med J       Date:  2015-08       Impact factor: 1.484

10.  Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.

Authors:  Mohamed Kadry Taher; Abdallah Alami; Christopher A Gravel; Derek Tsui; Lise M Bjerre; Franco Momoli; Donald R Mattison; Daniel Krewski
Journal:  JGH Open       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.